Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants

por Hibma, Jennifer E., O’Gorman, Melissa, Nepal, Sunil, Pawlak, Sylvester, Ginman, Katherine, Pithavala, Yazdi K.
Publicado 2021

Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants

por Hibma, Jennifer E., O’Gorman, Melissa, Nepal, Sunil, Pawlak, Sylvester, Ginman, Katherine, Pithavala, Yazdi K.
Publicado 2022

Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir

por Singh, Ravi Shankar P., Toussi, Sima S., Hackman, Frances, Chan, Phylinda L., Rao, Rohit, Allen, Richard, Van Eyck, Lien, Pawlak, Sylvester, Kadar, Eugene P., Clark, Frances, Shi, Haihong, Anderson, Annaliesa S., Binks, Michael, Menon, Sandeep, Nucci, Gianluca, Bergman, Arthur
Publicado 2022